» Articles » PMID: 19008912

Insulin Regulates SOCS2 Expression and the Mitogenic Effect of IGF-1 in Mesangial Cells

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2008 Nov 15
PMID 19008912
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Renal hypertrophy and deposition of extracellular matrix proteins are consistent findings in diabetic nephropathy and these processes can be halted or reversed by euglycemic control. Using DNA microarray analysis of glomerular RNA from control and diabetic rats we found that the expression levels of insulin-like growth factor 1 receptor (IGF-1R) were increased while those of suppressor of cytokine signaling 2 (SOCS2) and STAT5 were decreased. All of these changes were normalized by islet cell transplantation. Overexpression of SOCS2 in rat mesangial cells inhibited IGF-1-induced activation of extracellular signal-regulated kinase, which subsequently reduced type IV collagen and DNA synthesis, an effect due to interaction of SOCS2 with IGF-1R. Inhibition of SOCS2 overexpression by small interfering RNA suppressed IGF-1R-mediated actions by preventing phosphorylation of tyrosine 317 in the p66Shc adaptor protein; however, overexpression of either SOCS1 or SOCS3 did not affect IGF-1R signaling. Insulin directly increased STAT5 and SOCS2 expression in mesangial cells. This study shows that insulin can inhibit the mitogenic action of IGF-1 in mesangial cells by regulating STAT5/SOCS2 expression. Insulin deficiency may contribute to the mesangial expansion found in diabetes through reduced STAT5/SOCS2 expression.

Citing Articles

Gene-Based Network Analysis Reveals Prognostic Biomarkers Implicated in Diabetic Tubulointerstitial Injury.

Wu S, Li W, Chen B, Pei X, Cao Y, Wei Y Dis Markers. 2022; 2022:2700392.

PMID: 36092962 PMC: 9452978. DOI: 10.1155/2022/2700392.


The Effect of Polymorphisms on Type 2 Diabetes Mellitus Susceptibility and Diabetic Complications in the Chinese Han Population.

Pan J, Tong R, Deng Q, Tian Y, Wang N, Peng Y Pharmgenomics Pers Med. 2022; 15:65-79.

PMID: 35125882 PMC: 8809519. DOI: 10.2147/PGPM.S347018.


Growth Hormone and IGF1 Actions in Kidney Development and Function.

Gurevich E, Segev Y, Landau D Cells. 2021; 10(12).

PMID: 34943879 PMC: 8699155. DOI: 10.3390/cells10123371.


Renal effects of growth hormone in health and in kidney disease.

Haffner D, Grund A, Leifheit-Nestler M Pediatr Nephrol. 2021; 36(8):2511-2530.

PMID: 34143299 PMC: 8260426. DOI: 10.1007/s00467-021-05097-6.


Identification of key genes and pathways in IgA nephropathy using bioinformatics analysis.

Hu S, Wang D, Yuan F, Lei Q, Zhang Y, Cheng J Medicine (Baltimore). 2020; 99(30):e21372.

PMID: 32791747 PMC: 7386957. DOI: 10.1097/MD.0000000000021372.


References
1.
Mahadevan P, Larkins R, Fraser J, Dunlop M . Effect of prostaglandin E2 and hyaluronan on mesangial cell proliferation. A potential contribution to glomerular hypercellularity in diabetes. Diabetes. 1996; 45(1):44-50. DOI: 10.2337/diab.45.1.44. View

2.
Vinciguerra M, Mordasini D, Vandewalle A, Feraille E . Hormonal and nonhormonal mechanisms of regulation of the NA,K-pump in collecting duct principal cells. Semin Nephrol. 2005; 25(5):312-21. DOI: 10.1016/j.semnephrol.2005.03.006. View

3.
Tack I, Elliot S, Potier M, Rivera A, Striker G, Striker L . Autocrine activation of the IGF-I signaling pathway in mesangial cells isolated from diabetic NOD mice. Diabetes. 2002; 51(1):182-8. DOI: 10.2337/diabetes.51.1.182. View

4.
Krebs D, Hilton D . SOCS: physiological suppressors of cytokine signaling. J Cell Sci. 2000; 113 ( Pt 16):2813-9. DOI: 10.1242/jcs.113.16.2813. View

5.
Young B, Johnson R, Alpers C, Eng E, Gordon K, Floege J . Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int. 1995; 47(3):935-44. DOI: 10.1038/ki.1995.139. View